SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 178.77 |
| Enterprise Value ($M) | 258.25 |
| Book Value ($M) | 111.82 |
| Book Value / Share | 5.24 |
| Price / Book | 1.60 |
| NCAV ($M) | 31.32 |
| NCAV / Share | 1.47 |
| Price / NCAV | 5.71 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.31 |
| Return on Assets (ROA) | -0.24 |
| Return on Equity (ROE) | -0.55 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 5.47 |
| Current Ratio | 5.47 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 268.14 |
| Assets | 348.64 |
| Liabilities | 236.83 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 67.64 |
| Operating Income | -121.69 |
| Net Income | -116.05 |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -78.76 |
| Cash from Investing | 58.23 |
| Cash from Financing | -27.63 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13D/A | Luly Jay R. | |||
| 13G/A | Farallon Capital Partners, L.P. | |||
| 13G | Integrated Core Strategies (us) Llc | |||
| 13G/A | Armistice Capital, Llc | 4.72 | -51.55 | |
| 13G/A | Millennium Management Llc | 3.50 | -44.39 | |
| 13G | Krensavage Asset Management, LLC | |||
| 13G/A | Vanguard Group Inc | 8.52 | 17.84 | |
| 13G/A | BlackRock, Inc. | 9.20 | -2.19 | |
| 13G/A | State Street Corp | 2.02 | -71.85 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 57,236 | 312,857 | 18.29 | |
| 78,855 | 628,401 | 12.55 | |
| 108,219 | 643,281 | 16.82 | |
| 68,147 | 456,774 | 14.92 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| EDIT – Editas Medicine, Inc. | ELEV – Elevation Oncology, Inc. |
| ELVN – Enliven Therapeutics, Inc. | ERAS – Erasca, Inc. |
| EWTX – Edgewise Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io